Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for heart failure with reduced ejection fraction in adults with HIV
IRCT20130719014054N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in heart failure (HF) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Efficacy in improving heart failure symptoms and Safety and side effects. Started Jun 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on IRCT20130719014054N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130719014054N2.